South Korean sensation PSY and his viral smash hit “Gangnam Style” have danced, rapped and ridden straight into the Guinness Book of World Records.
PSY’s video has been liked 2,234,641 times on YouTube, an all-time high, annihilating the prior record of 1,575,979, set by LMFAO’S “Party Rock Anthem.”
All in a mere three months after “Gangnam Style” was released.
Heeeeeey sexy laaaaaady! Bow down to PSY and his fake horse.
As for the all-time most watched YouTube video, PSY's got a ways to go before he catches Justin Bieber and his 780,683,863 views. "Baby," that's a lot.
“Gangnam Style” has a modest 230,549,340. So far.
Whether he breaks that mark or not, PSY already left his mark on pop culture, thanks to the Britney Spears Gangnam Style dance on Ellen. Enough said.
Sehmel Homestead Park is an oasis of soccer and football fields, tennis and basketball courts, trails, and a large play structure. Kids will especially enjoy the colorful nature of the slides, see-saws, bridges, and monkey bars. This 98-acre park site is located about two miles west of the Burnham Dr. exit, off of Hwy. 16, at the intersection of Sehmel Dr. and 78th Ave. NW. The park is available for party or sporting rentals, and plenty of parking is available.
Documenting women's experiences with chromosome abnormalities found in new prenatal testPublic release date: 21-Sep-2012 [ | E-mail | Share ]
Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine
Responses range from 'needing support' to worried about 'toxic knowledge'
PHILADELPHIA We often hear that "knowledge is power." But, that isn't always the case, especially when the knowledge pertains to the health of an unborn child, with murky implications, at best. A new study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, begins to document this exception to the general rule.
Barbara Bernhardt, MS, CGC, a genetic counselor at the Hospital of the University of Pennsylvania, and colleagues contacted a small group of women who are participating in a larger Columbia University study investigating the use of a genetic test called a DNA microarray to identify the possibility of prenatal chromosomal abnormalities. Bernhardt is also co-director of the Penn Center for the Integration of Genetic Healthcare Technologies.
The study's goal: To document a woman's experience upon learning that her child's genetic material contained chromosomal abnormalities. The women's responses to this type of news were mostly negative, ranging from saying they "needed support" after getting the results to describing the results as "toxic knowledge," that they wish they hadn't received.
DNA microarrays represent a relatively new approach to genetic testing. Classically, chromosomal abnormalities are detected with karyotyping, which uses DNA staining and microscopy to identify such large-scale abnormalities as trisomy 21, associated with Down's syndrome. Yet the technique lacks the resolution to detect smaller yet still significant -- chromosomal changes.
That's where DNA microarrays come in. Microarrays use an array of DNA "probes" to search for matching bits of DNA from across the genome. In theory, if a piece of DNA is missing or duplicated, that change can be detected on a microarray, even if it is too small to be detected by karyotyping.
DNA microarrays are often used by physicians following birth to identify chromosomal abnormalities in children with unexplained developmental delays or congenital defects. However, the technique is also being applied prenatally. The problem, though, unlike some genetic changes that definitely lead to disease, is that the significance of the changes DNA microarrays identify (called copy-number variants) isn't always clear. Nor is it necessarily obvious what actions parents, doctors, and genetic counselors should take in light of the findings.
Bernhardt set out to document the experiences of women receiving such information. Of the 4,450 women enrolled in the Columbia University trial, Bernhardt and her team selected 54 who had received chromosome microarray results that showed abnormalities in the previous six months. Of those, they interviewed 23 regarding the subjects' recollections of their informed-consent discussions, genetic counseling, test results, and follow-up.
The team identified five "key elements" that describe the women's experiences:
"An offer too good to pass up." Many of the women accepted the offer for testing because it was offered at no cost and posed no additional risk to them or their unborn child. Yet they did so without necessarily considering the potential significance and ambiguity of the information they could receive.
"Blindsided by the results." Women reported being caught off-guard by the microarray data, which generally arrived one to two weeks after preliminary (and seemingly normal) karyotype information.
"Uncertainty and unquantifiable risks." Women had difficulty making sense of the test results, as copy-number variants are often of either uncertain clinical significance, or produce a wide array of possible developmental outcomes. As a result, the women's time-critical and emotionally charged decisions about whether to terminate a pregnancy, for instance, were complicated.
"Need for support." The women reported needing support from counselors, spouses or partners to digest and consider the information they had received and to make critical decisions regarding their pregnancies.
"Toxic knowledge." The women noted that in many cases the array results constituted "toxic knowledge" that they, in retrospect, wish they hadn't learned, because it negatively impacted their pregnancy, birth, and postnatal experiences. As Bernhardt describes it, "They watch their babies like hawks, always waiting for the other shoe to drop."
According to Bernhardt, chromosomal microarrays pose the same ambiguities after birth as prenatally. The difference is that postnatal testing is done because the child already exhibits an unexplained abnormality, and physicians hope the test can pinpoint its cause. "But when you find [an abnormality] in a fetus it puts the woman and couple into a tailspin because they have no clue what to expect," she says. "And the couple is immediately faced with whether or not to terminate the pregnancy."
The take-home message, Bernhardt says, is that genetic counselors must be prepared to spend more time with parents to help them explore their reasons for wanting microarray testing. Counselors also need to emphasize to parents the potentially ambiguous nature of the microarray results, how to consider potential responses, and how to make the best decisions they can based on both available scientific data and the clients' beliefs.
The study, "Women's experiences receiving abnormal prenatal chromosomal microarray testing results," was published online September 6 in the journal Genetics in Medicine. Additional authors include Penn researcher Danielle Soucier; as well as Karen Hanson, Melissa Savage, and Ronald Wapner from Columbia University College of Physicians and Surgeons; and Laird Jackson, Drexel University College of Medicine.
###
This work was supported by funding from the National Human Genome Research Institute, National (P50HG004487) and from the National Institute of Child Health and Development (R01HD055651-01 and R01HD055651-03S1).
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Documenting women's experiences with chromosome abnormalities found in new prenatal testPublic release date: 21-Sep-2012 [ | E-mail | Share ]
Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine
Responses range from 'needing support' to worried about 'toxic knowledge'
PHILADELPHIA We often hear that "knowledge is power." But, that isn't always the case, especially when the knowledge pertains to the health of an unborn child, with murky implications, at best. A new study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, begins to document this exception to the general rule.
Barbara Bernhardt, MS, CGC, a genetic counselor at the Hospital of the University of Pennsylvania, and colleagues contacted a small group of women who are participating in a larger Columbia University study investigating the use of a genetic test called a DNA microarray to identify the possibility of prenatal chromosomal abnormalities. Bernhardt is also co-director of the Penn Center for the Integration of Genetic Healthcare Technologies.
The study's goal: To document a woman's experience upon learning that her child's genetic material contained chromosomal abnormalities. The women's responses to this type of news were mostly negative, ranging from saying they "needed support" after getting the results to describing the results as "toxic knowledge," that they wish they hadn't received.
DNA microarrays represent a relatively new approach to genetic testing. Classically, chromosomal abnormalities are detected with karyotyping, which uses DNA staining and microscopy to identify such large-scale abnormalities as trisomy 21, associated with Down's syndrome. Yet the technique lacks the resolution to detect smaller yet still significant -- chromosomal changes.
That's where DNA microarrays come in. Microarrays use an array of DNA "probes" to search for matching bits of DNA from across the genome. In theory, if a piece of DNA is missing or duplicated, that change can be detected on a microarray, even if it is too small to be detected by karyotyping.
DNA microarrays are often used by physicians following birth to identify chromosomal abnormalities in children with unexplained developmental delays or congenital defects. However, the technique is also being applied prenatally. The problem, though, unlike some genetic changes that definitely lead to disease, is that the significance of the changes DNA microarrays identify (called copy-number variants) isn't always clear. Nor is it necessarily obvious what actions parents, doctors, and genetic counselors should take in light of the findings.
Bernhardt set out to document the experiences of women receiving such information. Of the 4,450 women enrolled in the Columbia University trial, Bernhardt and her team selected 54 who had received chromosome microarray results that showed abnormalities in the previous six months. Of those, they interviewed 23 regarding the subjects' recollections of their informed-consent discussions, genetic counseling, test results, and follow-up.
The team identified five "key elements" that describe the women's experiences:
"An offer too good to pass up." Many of the women accepted the offer for testing because it was offered at no cost and posed no additional risk to them or their unborn child. Yet they did so without necessarily considering the potential significance and ambiguity of the information they could receive.
"Blindsided by the results." Women reported being caught off-guard by the microarray data, which generally arrived one to two weeks after preliminary (and seemingly normal) karyotype information.
"Uncertainty and unquantifiable risks." Women had difficulty making sense of the test results, as copy-number variants are often of either uncertain clinical significance, or produce a wide array of possible developmental outcomes. As a result, the women's time-critical and emotionally charged decisions about whether to terminate a pregnancy, for instance, were complicated.
"Need for support." The women reported needing support from counselors, spouses or partners to digest and consider the information they had received and to make critical decisions regarding their pregnancies.
"Toxic knowledge." The women noted that in many cases the array results constituted "toxic knowledge" that they, in retrospect, wish they hadn't learned, because it negatively impacted their pregnancy, birth, and postnatal experiences. As Bernhardt describes it, "They watch their babies like hawks, always waiting for the other shoe to drop."
According to Bernhardt, chromosomal microarrays pose the same ambiguities after birth as prenatally. The difference is that postnatal testing is done because the child already exhibits an unexplained abnormality, and physicians hope the test can pinpoint its cause. "But when you find [an abnormality] in a fetus it puts the woman and couple into a tailspin because they have no clue what to expect," she says. "And the couple is immediately faced with whether or not to terminate the pregnancy."
The take-home message, Bernhardt says, is that genetic counselors must be prepared to spend more time with parents to help them explore their reasons for wanting microarray testing. Counselors also need to emphasize to parents the potentially ambiguous nature of the microarray results, how to consider potential responses, and how to make the best decisions they can based on both available scientific data and the clients' beliefs.
The study, "Women's experiences receiving abnormal prenatal chromosomal microarray testing results," was published online September 6 in the journal Genetics in Medicine. Additional authors include Penn researcher Danielle Soucier; as well as Karen Hanson, Melissa Savage, and Ronald Wapner from Columbia University College of Physicians and Surgeons; and Laird Jackson, Drexel University College of Medicine.
###
This work was supported by funding from the National Human Genome Research Institute, National (P50HG004487) and from the National Institute of Child Health and Development (R01HD055651-01 and R01HD055651-03S1).
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Changes to business risk management programs under the Growing Forward agreement signed Friday by the federal, provincial and territorial governments are not supported by Keystone Agricultural Producers.
?Both AgriInvest and AgriStability have been diluted ? AgriStability to the point that it is questionable whether the original goal of the program is being met,? said KAP president Doug Chorney.
?It used to attempt to ensure economic stability for the farm sector and now it has a much-diminished ability to do this.?
He said a new component to AgriStability called a ?limited reference margin? puts a cap on the amount of income protection a farmer can access. Under the original program, a farmer?s reference margin determined the coverage that AgriStability would provide, but now, that is no longer the case.
Enrolling in AgriStability requires complicated financial paperwork that is often done with the help of an accountant, he further noted, with significant costs that may make it hard to justify.
?This is a slap in the face for farmers and farm groups ? because governments held consultations with us, and I can assure you that virtually no one in primary production would have agreed to this,? he said.
Also troubling, said Chorney, is the change to AgriInvest ? a program that allowed a farmer to put up to 1.5 per cent of yearly allowable net sales into an account that was matched by governments, to a maximum of $22,500 per year. That percentage has been dropped to one per cent, or a maximum of $15,000 per year.
?This was a good business risk management tool, and now it is less effective,? he noted.
Chorney said KAP wants to work with governments in the hopes of modifying business risk management programming during the monitoring and reviewing process that has been promised over the course of the five-year agreement.
He also noted that not all programming has been finalized, and urged governments to act upon requests from the livestock industry to create a forage production insurance program, as well as price insurance on livestock.
If corporations are people now, why can?t rivers be?
Under a landmark agreement, signed in New Zealand earlier this summer, the Whanganui River has become a legal entity with a legal voice.
The agreement is the result of over a hundred years of advocacy by the Whanganui iwi, an indigenous community with a long history of reliance on the river and its bountiful natural resources.
The Whanganui, the third longest river in New Zealand, will be recognized as a person under the law ?in the same way a company is, which will give it rights and interests,? Christopher Finlayson, a spokesperson for the Minister of Treaty Negotiations, told the New Zealand Herald.
Organizations that work to protect the rights of indigenous communities worldwide are celebrating the agreement as an affirmation of the inextricable relationship between indigenous communities and natural ecosystems.
?The recognition of the personhood of the Whanganui River represents a landmark moment in legal history,? Suzanne Benally, the Executive Director of Cultural Survival, wrote in an email to TakePart. ?Nature cannot be seen solely as a resource to be owned, exploited and profited from; it is a living and sustaining force that needs to be honored, respected, and protected by all of us.?
Treehugger points out that this isn?t the first time the natural world has received monumental rights?or a good lawyer.
In 2008, Ecuador became the first nation in the world to recognize the legal rights of its mountains, rivers, and land.
Frustrated by the exploitation of the Amazon and the Andes by multinational mining and oil corporations, delegates in Ecuador turned to the Pennsylvania-based Community Environmental Legal Defense Fund to help rewrite the country?s constitution.
The delegates wanted to provide legal protection for Ecuador?s environment and its resources. The Legal Defense Fund helped them include a ?Rights of Nature? framework in their constitution that allows people to sue on behalf of an ecosystem.
In 2011, the new law got its first test. A suit was brought on against the Provincial Government of Loja, on behalf of the Vilcabama River in Ecuador.
The local Loja government had allowed a road that abutted the river to be widened, which forced rocks and debris into the watershed and caused large floods that affected communities living on its banks.
As a result of the ?rights of nature? provisions in Ecuador?s constitution, the judge decided in favor of the river. The municipality of Loja was forced to halt the project and rehabilitate the area.
Ecuador?s new constitution has been an inspiration to communities and governments all over the world who want greater protections for their local resources.
?People not only in the U.S. but also in other countries are saying to themselves that something is fundamentally wrong with our environmental legal frameworks,? says Mari Margil, associate director of the Community Environmental Legal Defense Fund.
?Temperatures are rising, fisheries are disappearing, and forests are being cutt down. We need to move to a different kind of environmental protection. Our current environmental laws are all about how much we can use or exploit nature,? she told TakePart.
Margil?s organization has worked with communities in New Hampshire, Virginia, and Pennsylvania to shift their thinking about how they can preserve and sustain their natural resources. Earlier this year, Margil and her colleagues helped launch the first ?rights of nature? organization in Italy.
The Clean Water Act, the Clean Air Act, and other current environmental laws actually legalize environmental harm by regulating how much pollution and degradation to an ecosystem is lawful, Margil says. Under existing law, nature is considered to be property.
The Legal Defense Fund is at the center of a movement that believes climate change and other growing international issues require new ways of thinking. ?Ecosystems and natural communities are not merely property that can be owned,? according to the organizaton?s website, ?but are entities that have an independent right to flourish.?
ScienceDaily (Sep. 18, 2012) ? Pancreatic cancer is highly lethal and difficult to detect early. In a new study, researchers report that people who had high levels of antibodies for an infectious oral bacterium turned out to have double the risk for developing the cancer. High antibody levels for harmless oral bacteria, meanwhile, predicted a reduced pancreatic cancer risk.
A new study finds significant associations between antibodies for multiple oral bacteria and the risk of pancreatic cancer, adding support for the emerging idea that the ostensibly distant medical conditions are related.
The study of blood samples from more than 800 European adults, published in the journal Gut, found that high antibody levels for one of the more infectious periodontal bacterium strains of Porphyromonas gingivalis were associated with a two-fold risk for pancreatic cancer. Meanwhile, study subjects with high levels of antibodies for some kinds of harmless "commensal" oral bacteria were associated with a 45-percent lower risk of pancreatic cancer.
"The relative increase in risk from smoking is not much bigger than two," said Brown University epidemiologist Dominique Michaud, the paper's corresponding author. "If this is a real effect size of two, then potential impact of this finding is really significant."
Pancreatic cancer, which is difficult to detect and kills most patients within six months of diagnosis, is responsible for 40,000 deaths a year in the United States.
Several researchers, including Michaud, have found previous links between periodontal disease and pancreatic cancer. The Gut paper is the first study to test whether antibodies for oral bacteria are indicators of pancreatic cancer risk and the first study to associate the immune response to commensal bacteria with pancreatic cancer risk. The physiological mechanism linking oral bacteria and pancreatic cancer remains unknown, but the study strengthens the suggestion that there is one.
"This is not an established risk factor," said Michaud, who is also co-lead author with Jacques Izard, of the Forsyth Institute and Harvard University. "But I feel more confident that there is something going on. It's something we need to understand better."
Izard, a microbiologist, said the importance of bacteria in cancer is growing. "The impact of immune defense against both commensals and pathogenic bacteria undeniably plays a role," he said. "We need to further investigate the importance of bacteria in pancreatic cancer beyond the associated risk."
Prospective, controlled study
To conduct their research, Michaud and Izard drew on medical records and preserved blood samples collected by the Imperial College-led European Prospective Investigation into Cancer and Nutrition Study, a massive dataset of more than 500,000 adults in 10 countries. Detailed health histories and blood samples are available from more than 380,000 of the participants.
From that population, the researchers found 405 people who developed pancreatic cancer, but no other cancer, and who had blood samples available. The researchers also selected 416 demographically similar people who did not develop pancreatic cancer for comparison.
The researchers blinded themselves to which samples came from cancer patients and which didn't during their analysis of the blood, which consisted of measuring antibody concentrations for 25 pathogenic and commensal oral bacteria. In their study design and analysis they controlled for smoking, diabetes, body mass index, and other risk factors.
An important element of the study design was that date of the blood samples preceded the diagnosis of pancreatic cancer by as much as a decade, meaning that the significant difference in antibody levels were likely not a result of cancer.
Instead, the underlying mechanisms that link Porphyromonas gingivalis to pancreatic cancer could be causal, Michaud said, although much more research is needed to understand this association.
Meanwhile, the researchers speculate, the association of high levels of antibodies for commensal bacteria and pancreatic cancer, may indicate an innate, highly active immune response that is protective against cancer.
"Genetic determinants of immune surveillance clearly play a critical role in pancreatic cancer development," the authors wrote. "Consequently, it is plausible that elevated levels of antibodies to oral bacteria in individuals serve as a marker for a genetically stronger immune response, providing protection against carcinogenesis."
Michaud, who studies cancer risk factors generally, continues to investigate the association between oral bacteria and pancreatic cancer in collaboration with Izard.
The National Cancer Institute was the primary funder of the study.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Brown University.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
Dominique S Michaud, Jacques Izard, Charlotte S Wilhelm-Benartzi, Doo-Ho You, Verena A Grote, Anne Tj?nneland, Christina C Dahm, Kim Overvad, Mazda Jenab, Veronika Fedirko, Marie Christine Boutron-Ruault, Fran?oise Clavel-Chapelon, Antoine Racine, Rudolf Kaaks, Heiner Boeing, Jana Foerster, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Carlotta Sacerdote, Sabina Sieri, Domenico Palli, Rosario Tumino, Salvatore Panico, Peter D Siersema, Petra HM Peeters, Eiliv Lund, Aurelio Barricarte, Jos?-Mar?a Huerta, Esther Molina-Montes, Miren Dorronsoro, J Ram?n Quir?s, Eric J Duell, Weimin Ye, Malin Sund, Bj?rn Lindkvist, Dorthe Johansen, Kay-Tee Khaw, Nick Wareham, Ruth C Travis, Paolo Vineis, H Bas Bueno-de-Mesquita, Elio Riboli. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut, 18 September 2012 DOI: 10.1136/gutjnl-2012-303006
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.